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Porphyrias are rare diseases caused by altered haem 
synthesis leading to the accumulation of different haem 
intermediates. Neurovisceral attacks may occur in acu­
te porphyrias, while photosensitivity is the presenting 
symptom in cutaneous porphyrias. We present here an 
overview of symptoms and a flowchart for the diagno­
sis of cutaneous porphyrias, with recommendations for 
monitoring and an update of treatment options. From 
the Danish Porphyria Register, we present the inciden­
ces and approximate prevalences of cutaneous por­
phyrias within the last 25 years. A total of 650 patients 
with porphyria cutanea tarda were identified, 73 with 
erythro poietic protoporphyria, 9 with variegate porp­
hyria, 4 with hereditary coproporphyria and one with 
congenital erythropoietic porphyria. The total incidence 
of all porphyrias was ~0.52/100,000 per year. Key words: 
cutaneous porphyrias; orphan disease; Denmark.
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Porphyrias are diseases caused by reduced activity of an 
enzyme involved in haem biosynthesis (Fig. 1) resulting 
in accumulation of haem intermediates in the skin, liver 
and red blood cells (1). Clinically, porphyrias are divided 
into acute and cutaneous types. Patients with cutaneous 
porphyria are light sensitive due to the accumulation of 
phototoxic porphyrins in the skin, and they may develop 
acute and chronic skin damage following sun exposure. 
Porphyrins absorb light with an absorption maximum 
of 400–410 nm and excited porphyrins transfer energy 
into chemical reactions, resulting in cellular damage 
and inflammation (2). Patients with erythropoietic pro-
toporphyria (EPP) develop acute painful reactions on 
light-exposed areas of the skin after short stays in the 
sun. Patients with porphyria cutanea tarda (PCT) have 
a more delayed response to light exposure and develop 
blisters and sores. Unlike PCT, patients with variegate 
porphyria (VP) and hereditary coproporphyria (HCP) 
can develop acute neurovisceral symptoms in addition 
to skin symptoms.
This article provides an overview of clinical symp-
toms, a diagnostic strategy and treatment options of 
cutaneous porphyrias, together with the Danish cases 
registered biochemically in the period 1989 to 20131.
ERYTHROPOIETIC PROTOPORPHYRIA
EPP is a disease of the bone marrow causing skin 
symptoms that may be complicated by hepatic invol-
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1In 1990 a national porphyria centre was established at Odense University 
Hospital, where biochemical and molecular genetic diagnostics are now 
centralized (3). As a unique feature, Denmark has a porphyria register, 
originally founded in 1955 by physician Torben K. With, together with his wife, 
affiliated to the Central Laboratory and Blood Bank, Svendborg Hospital. They 
created a Danish porphyria register containing 349 patients with porphyria 
and 1,600 of the patients’ relatives (4). Subsequently, physician Axel Brock 
continued the registration of patients with porphyria at the Department of 
Clinical Biochemistry, Viborg Hospital, until 2013 when the registration 
was passed on to the porphyria laboratory at Odense University Hospital.
Fig. 1. Haem synthesis and porphyria diseases. Uroporphyrinogen I 
and coproporphyrinogen I isomers are created non-enzymatically and 
only uroporphyrinogen III and coproporphyrinogen III isomers can be 
metabolized into haem. ADP: ALA-dehydratase deficient porphyria; AIP: 
acute intermittent porphyria; CEP: congenital erythropoietic porphyria; 
EPP: erythropoietic protoporphyria; HCP: hereditary coproporphyria; HEP: 
hepatoerythropoietic porphyria; PCT: porphyria cutanea tarda; XLDPP: 
X-linked dominant protoporphyria; VP: variegate porphyria.
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vement. EPP is caused by mutations in the gene FECH 
encoding the enzyme ferrochelatase (Fig. 1). The 
disease has a complex inheritance and often patients 
have a combination of 1 FECH mutation (inactive al-
lele) in combination with a low activity allele (5). In 
a few families, patients are homozygous or compound 
heterozygous for FECH mutations, and these patients 
appear to have an increased risk of severe liver disease 
(6). The prevalence of EPP has been calculated in a 
number of European countries, and ranged from 1.5 
(Poland) to 27.7 (Norway) per million inhabitants (7). 
EPP is the most prevalent porphyria in children, and 
patients have a lifelong acute reaction to light. We 
identified a total of 73 patients with EPP in the period 
1989 to 2013, which gives a prevalence of ~13 per 
million inhabitants. A Danish study with clinical data 
from 29 patients has been published earlier (8).
Protoporphyrin is lipophilic and accumulates in the 
endothelium of blood vessels in the skin’s dermis. It is 
excreted in the bile and can cause liver diseases, such 
as cirrhosis and gallstones. In rare cases intrahepatic 
cholestasis and terminal liver failure can occur. Pa-
tients with EPP can develop microcytic, hypochromic 
anaemia; however, iron supplements should be pre-
scribed with caution and only in cases with proven iron 
deficiency, because iron can exacerbate symptoms (9).
Patients with EPP develop acute burning sensations 
in the skin, oedema, erythema and, sometimes, purpura 
after sun exposure (Fig. 2A). The skin reaction can oc-
cur within minutes to a few hours, and can persist for 
several days. Eczematous and waxy skin can develop on 
the nose and knuckles (“old knuckles”) (Fig. 2B) as well 
as smaller scars and pseudorhagades around the mouth 
(10). In children, EPP should be suspected if the child 
is crying or complaining about pain in the skin during 
or after sun exposure. The diagnostic latency can be 
long; in some cases up to 40 years after the first symp-
tom (11, 12). The diagnosis of EPP is based on clinical 
symptoms and detection of elevated protoporphyrin in 
erythrocytes (Fig. 3) (13). Genetic investigation should 
be carried out if the disease is biochemically verified.
As patients with EPP often experience pain imme-
diately after sun exposure, they instinctively protect 
themselves against the sun. Unintended phototoxic 
skin reactions may be alleviated with cold compresses, 
topical application of corticosteroids and, possibly, 
antihistamines. EPP has traditionally been treated with 
high-dose β-carotene, which colours the skin yellow by 
carotene pigment and acts as an antioxidant. This treat-
ment is not effective for all patients, however, but can 
be tried (14). A Danish study investigated the efficacy 
of p.o. zinc 200 mg 3 times a day, based on the hypo-
thesis that zinc may reduce iron absorption from the 
gut. This treatment reduced light-sensitivity and pain 
in the skin in 71% of patients, based on self-reported 
end-points and historical data (15). Afamelanotide, 
a melanocyte-stimulating hormone for subcutaneous 
administration, has been approved by the European 
Medicines Agency with orphan drug status in October 
2014. Afamelanotide increases the production of the 
photo-protective pigment eumelanin, which absorbs 
and scatters light without causing cellular damage (16). 
However, the drug is not yet approved or marketed in 
Denmark. Phototherapy treatment can be used with 
narrow-band ultraviolet B (UVB) (TL01). Porphyrins 
excitation maximum is 400–410 nm, while narrow-band 
UVB (TL 01) has a wavelength of 311–313 nm. The 
exact mechanism is not known, but is thought to in-
clude thickening of the stratum corneum and epidermis, 
induction of melanin and suppression of the immune 
system (17). Cholestyramine or activated charcoal may 
be used if there is sign of serious liver involvement (5, 
6). Ultimately, liver transplant can be life-saving and 
bone marrow transplantation can be carried out in order 
to prevent recurrence of liver disease (18).
Patients should be cautious with alcohol intake and 
are advised to avoid hepatotoxic medications. Some 
recommend vaccination against hepatitis A and B (19, 
20). Patients with EPP should be monitored, with pa-
rameters reflecting liver function, haematology, iron 
status, vitamin D and erythrocyte protoporphyrin, 
every 6–12 months. Ultrasound of the liver and further 
hepatological assessments can be performed as needed.
X-LINKED DOMINANT PROTOPORPHYRIA
This is a new porphyria variant clinically resembling 
EPP. No Danish cases of this subtype of porphyria have 
Fig. 2. Patient with erythropoietic protoporphyria and acute phototoxic reaction on the nose (A), lichenified skin on the dorsum of fingers (B). Bullae, 
erosions and crusted lesions on (C) the hand and (D) the foot in patients with porphyria cutanea tarda.
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been reported until now. Patients have elevated erythro-
cyte protoporphyrin but not decreased activity of FECH. 
There is, however, a gain of function mutation in ALAS2. 
Diagnosis and treatment principles are as in EPP (6).
PORPHYRIA CUTANEA TARDA
PCT is a hepatocutaneous porphyria caused by reduced 
activity of uroporphyrinogen decarboxylase (UROD) 
(see Fig. 1). PCT is found in a sporadic form (sPCT) 
with no detectable mutation and an inherited form, 
familial PCT (fPCT) with mutation in the gene UROD. 
The disease fPCT is inherited in an autosomal dominant 
way with reduced penetrance (21, 22). The prevalence 
of symptomatic PCT varies geographically, with a pre-
valence in Sweden and Norway of 1 per 10,000 (23, 24). 
We identified 650 patients with PCT in the period 1989 
to 2013, which corresponds to ~1 per 10,000 inhabitants.
Patients with PCT typically become symptomatic 
around the age of 40–50 years, but the familial form 
may occur earlier. Patients develop blisters, erosions 
and ulcers on light-exposed areas of the skin (see Fig. 
2C and D) making the face, back of the hands, forearms 
and feet particularly vulnerable. The skin heals slowly, 
leaving scars and milia. The symptoms are most com-
mon in summer and autumn months. Hyperpigmenta-
tion and hypertrichosis may occur. A distinctive, and 
often early, symptom is vulnerable skin.
Risk factors for developing PCT are hepatitis C in-
fection, HIV infection, alcohol intake, and oestrogen-
containing medicines. These risk factors often occur 
in combination (25). Patients often have some degree 
of iron overload and the incidence of mutations in the 
hemochromatosis-related genes is increased compared 
with the background population (26). Several studies 
have shown increased incidences of diabetes, liver cir-
rhosis and hepatocellular carcinoma (20, 21, 27).
The diagnosis of PCT is made on clinical features 
combined with measurement of porphyrins in the urine, 
faeces and plasma (see Fig. 3) (13). In the active disease 
state, one can see red fluorescence of urine and fluid 
from blisters by illumination with long-wave UV light 
(21). VP and HCP may have similar pattern excretion in 
urine, and therefore these conditions must be excluded 
by measuring porphyrins in plasma and excretion pat-
tern in faeces (Fig. 3) (13). fPCT can be investigated 
by genetic testing (21).
Patients with PCT should avoid excessive alcohol in-
take, oestrogen use and unnecessary iron treatment. Sun 
exposure is primarily limited by protective clothing, 
cessation of sunbathing and tanning use, and the use of 
sun-blockers. In addition, phlebotomy and/or low-dose 
hydroxychloroquine can be used. Low-dose hydroxy-
chloroquine probably works by increasing the excretion 
of water-soluble porphyrins (21, 28, 29). Phlebotomies 
deplete the liver iron content and reduce porphyrins in 
plasma and urine. Treatment can be effective in patients 
with and without iron overload. Clinical remission is 
typically achieved after 5–7 phlebotomies of 350–500 
ml. Phlebotomies are particularly well chosen in pa-
tients with haemochromatosis. If the above treatments 
are contraindicated, iron-chelating compounds may be 
used. Treatment of PCT probably reduces the risk for 
developing HCC.
In the active treatment periods, porphyrin concen-
trations should be monitored in urine or plasma every 
third month and, after that, once yearly until complete 
remission.
Fig. 3. Flowchart for diagnosing cutaneous porphyria with biochemical characteristics. Urine, plasma, faeces and/or whole blood is forwarded to the 
Department of Clinical Biochemistry and Pharmacology, Odense University Hospital. ↑: increased; →: normal. CEP: congenital erythropoietic porphyria; 
EPP: erythropoietic protoporphyria; HEP: hepatoerythropoietic porphyria; HCP: hereditary coproporphyria; Copro: coproporphyrin; PBG: porphobilinogen; 
PCT: porphyria cutanea tarda; VP: variegate porphyria; XLDPP: X-linked dominant protoporphyria.
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PSEUDOPORPHYRIA AND PORPHYRIA 
CUTANEA TARDA IN DIALYSIS PATIENTS
Patients with pseudoporphyria have skin manifesta-
tions that clinically and histologically imitate PCT. 
These patients, however, have normal haem metabo-
lism and are not included in the porphyria register. The 
condition may occur in patients treated with various 
phototoxic drugs, especially in patients with chronic 
renal failure receiving high-dose diuretics. Dialysis 
patients may have elevated concentration of porphyrins 
in plasma due to insufficient dialysis and can be dis-
tinguished from patients with PCT by the quantity of 
porphyrins in plasma (30).
The treatment of PCT in dialysis patients is a chal-
lenge, since dialysis patients often have anaemia, which 
contraindicates phlebotomy. Anti-malarial treatment 
is ineffective, since mobilized porphyrins cannot be 
eliminated by standard haemodialysis or peritoneal 
dialysis. Instead high-flux dialysis or treatment with 
erythropoietin ± low-volume phlebotomy may be at-
tempted (31–33).
VARIEGATE PORPHYRIA AND HEREDITARY 
COPROPORPHYRIA
VP and HCP occur due to mutations in the genes co-
ding for the protoporphyrinogen oxidase (PPOX) and 
coproporphyrinogen oxidase (CPOX), respectively. 
Both diseases are inherited in an autosomal dominant 
manner with incomplete penetrance. VP is rare, with 
a prevalence in Europe ranging from 0.4 (Poland) to 
10.4 (Switzerland) per million inhabitants (7). In South 
Africa, VP is much more frequent (34). HCP occur with 
a prevalence of approximately 1/100,000 (35). Since 
1989 we have registered 9 patients with VP and 4 with 
HCP in Denmark. 
Patients with HCP and VP may have PCT-like skin 
lesions or acute episodic neurovisceral attacks or both. 
Symptoms of acute neurovisceral attacks, which can 
be life-threatening (36), are abdominal pain, vomiting, 
constipation, hypertension, tachycardia, fever, muscle 
weakness, fatigue, paresis, sensory disturbances, seizu-
res, mental instability or hallucinations (3, 34).
RARE RECESSIVE PORPHYRIAS
Congenital erythropoietic porphyria (CEP), Günther’s 
disease, is a recessive disease presenting in early child-
hood with red-coloured urine in diapers (37). Only one 
patient has been diagnosed in Denmark hitherto. These 
patients are very sensitive to light and develop blisters 
and scarring after exposure to sunlight. Deformity 
of the nose, ears and the distal parts of fingers and 
toes may occur. Hyperpigmentation, hypertrichosis, 
scarring alopecia and scleromalacia can also be seen. 
Teeth and bones are reddish-brown due to deposition 
of porphyrins. Hepatoerythropoietic porphyria (HEP) 
is caused by homozygous or compound heterozygous 
mutations in UROD. There are no patients with HEP 
registered in Denmark. The symptoms are as in patients 
with CEP.
At the National Board of Health and European 
Commission level there is increased focus on rare di-
seases, and collaboration with patient organizations is 
highlighted in the national strategy for rare diseases in 
Denmark. In Scandinavia, the patients with porphyria 
are organized in the following patient associations: with 
Porfyriforeningen in Denmark (www.porfyriforeningen.
dk), Riksföreningen mot porfyrisjukdomar (www.por-
fyri.se) in Sweden and Norsk Porfyriforening (www.
porfyri.no) in Norway. 
Although the porphyrias are all caused by decreased 
activity of an enzyme in haem biosynthesis, there are 
differences in clinical and biochemical appearance and 
treatment possibilities. EPP should be suspected when 
a child or adult patient has painful and immediate skin 
reactions to the sun; while PCT is characterized by 
delayed skin reactions to sun mostly in adults. When 
using the diagnostic flow diagram given in this article 
the patients can be given a correct diagnoses and gui-
dance on precautions and medical therapy.
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